From the results of PI3K/AKT signaling pathway enriched in KEGG (Figure 2(e)), we predicted that PI3K/AKT/NF-κB signaling pathway may participate in the inhibitory effects of EF on prostate cancer since NF-κB is a key transcription factor downstream of PI3K/AKT to mediate prostate carcinogenesis [21], which is also consistent with the results of GO enrichment featuring transcription factor binding (Figures 2(a) and 2(b)). The gene discussed is AKT1; the disease is medical procedure.